Close Menu

CHICAGO (GenomeWeb) – Envisagenics, a startup focused on aiding drug discovery by applying artificial intelligence to gene sequences, has closed a $2.4 million seed round of venture capital.

The lead investors are mostly women, including Daniella Kranjac, managing director of Dynamk Capital; Shana Fisher, founder of Third Kind Venture Capital; and Gillian Sandler, of New York biotech investment company Cosine, the firm said. Envisagenics also received funding from Peter Thiel's Breakout Labs and from the New York State Innovation Venture Capital Fund.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.